Systems and methods are provided for a non-invasive high resolution pressure pulse waveform measurement system. The system may include a blood pressure cuff, an air pump to inflate the blood pressure cuff to specific pressure levels, high resolution pressure sensors configured to perform high sensitivity signal acquisition at a specified pressure level, high range pressure sensors configured to measure an absolute reference for the signal and to calibrate the signal, pneumatic tubing connecting the air pump and sensors with the cuff, and a hydrodynamic filter configured as an input to a reference port of the high resolution pressure sensor. The hydrodynamic filter may be configured to transmit only mean pressure by attenuating a selected frequency range of the signal.
A61B 5/02 - Mesure du pouls, du rythme cardiaque, de la pression sanguine ou du débit sanguin; Détermination combinée du pouls, du rythme cardiaque, de la pression sanguine; Evaluation d'un état cardio-vasculaire non prévue ailleurs, p.ex. utilisant la combinaison de techniques prévues dans le présent groupe et des techniques d'électrocardiographie; Sondes cardiaques pour mesurer la pression sanguine
Systems and methods disclosed herein relate to the detection of irregular particles in a blood flow based on a determined relative speed of a particle suspended in a blood flow and/or other properties of a particle suspended in a blood flow including a particle's relative position within a blood vessel and a particles tendency to cluster with other particles suspended in a blood flow. Based on a determined relative speed and/or other relevant factors, the properties of irregular particles may also be measured, including the size, shape, and frequency of irregular particles in a blood flow. Machine learning techniques may be employed to determine patterns for the behavior of irregular particles suspended in a blood flow. These patterns may correspond to particular health risks and conditions.
Disclosed herein include methods, compositions, and kits suitable for use in vaccination. There are provided, in some embodiments, nucleic acid compositions (e.g., mRNA vaccine, DNA vaccine) comprising a polynucleotide encoding a fusion protein. The fusion protein can comprise an antigenic polypeptide (AP) and an endosomal sorting complex required for transport (ESCRT)-recruiting domain (ERD). A plurality of fusion proteins can be capable of self-assembling into an enveloped nanoparticle (ENP) secreted from a cell in which the fusion proteins are expressed. There are provided, in some embodiments, populations of ENPs.
Disclosed herein is a composition for linked amplification tethered with exponential radiance for signal amplification. Also disclosed herein, is a kit for linked amplification tethered with exponential radiance for signal amplification. Also disclosed herein, is a method linked amplification tethered with exponential radiance for signal amplification.
A system of a multi-rotor aircraft that capitalizes on the advantages of fixed wing elements combined with rotary wing structures. The fixed wing elements can help to generate lift once the aircraft is airborne and can thus reduce the need for larger lifting rotors which can allow for longer flight times and distances. Additionally, the systems disclosed herein take advantage of a partial in-wing configuration with a number of rotors to reduce the overall footprint of the vehicle while maintaining the flight efficiency that comes with combining features of fixed and rotary wing elements, and increasing operator safety by shrouding rotating parts. The unique configurations allow for a decoupling of the pitch, yaw and roll authority to reduce the complexity in control systems and improve the flight efficiency of the aircraft. Additional configurations implement the use of smaller thrust rotors that can be used to generate thrust as well as control yaw and thus counteract any remaining unbalanced torque.
A system and method for controlling a multi-rotor aircraft that implements the unconventional use of different sized rotors. The different sized rotors than the main rotors tend to generate an unbalanced torque and pitch on the aircraft that effectively decouples the pitch and yaw control from the main rotors. The atypical design tends to lend itself to improved control capabilities and simplified control systems. Additional configurations implement the use of smaller thrust rotors that can be used to generate thrust as well as control yaw and thus counteract any remaining unbalanced torque from the odd auxiliary rotor.
A network of high-resolution cameras for monitoring and controlling a drone within a specific operational environment such that the latency time for communication between the cameras and drone is less than that of human controlled drones. The drone can communication drone health data to the network of cameras where such information can be combined with visual image data of the drone to determine the appropriate flight path of the drone within the operational environment. The drone can then subsequently be controlled by the network of cameras by maintaining a constant visual image and flight control data of the drone as it operates within the environment.
Disclosed herein include circuits, compositions, nucleic acids, populations, systems, and methods enabling single circuits to generate multiple molecularly and functionally distinct states that are each stable across multiple cell division cycles. Synthetic circuits provided herein can stably exist in multiple distinct states characterized by differences in the concentrations and expression levels of its components. In the absence of changes to the external environment, each of these states can be stable. In some embodiments, transcription factors provided herein activate when dimerized, and show much weaker activity as monomers. In some embodiments, each transcription factor homodimer activates expression of its own gene. In some embodiments, transcription factors can form mixed heterodimers with one another that do not strongly activate any genes in the circuit. Different embodiments of the synthetic circuits provided herein can use different numbers of transcription factors to produce a growing number of stable states.
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiques; Thérapie génique
C12N 15/63 - Introduction de matériel génétique étranger utilisant des vecteurs; Vecteurs; Utilisation d'hôtes pour ceux-ci; Régulation de l'expression
C12N 15/90 - Introduction stable d'ADN étranger dans le chromosome
10.
MEMBRANE-BASED, IN-GEL LOOP-MEDIATED ISOTHERMAL AMPLIFICATION (LAMP) SYSTEM AND METHOD FOR DETECTING MICROBES
Disclosed herein is a membrane-based, in-gel loop-mediated isothermal amplification (LAMP) system, kit and method for detection of a target microorganism in a sample suspected of containing the microorganism. LAMP reagents, a lysing agent and a hydrogel are placed together on a filter membrane loaded with a pre-filtered sample. The hydrogel polymerizes over a short time to immobilize any target DNA/RNA particles on the membrane. The system may include a compact, portable device that integrates heat incubation and fluorescence illumination, and also a cloud-based smartphone image analysis application for quantitative results interpretation. If target DNA/RNA are present in the sample, fluorescent amplicons are produced as a result of LAMP reaction. The target microorganisms are detected by visually detecting the presence or absence of the amplicons. The method may be employed for rapid and inexpensive point-of-use (POU) absolute quantification of SARS-CoV-2 in environmental water or wastewater samples with high sensitivity.
C12Q 1/689 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p.ex. amorces ou sondes pour la détection ou l’identification d’organismes pour les bactéries
11.
MULTIVALENT CARRIERS AND RELATED VACCINE COMPOSITIONS
Disclosed herein include multivalent carriers comprising a plurality of heterologous coronavirus proteins antigens derived from different coronaviruses. The multivalent carriers herein described can elicit heterologous binding and neutralization properties against coronaviruses that differ from the coronaviruses from which the coronavirus antigens are derived to produce the multivalent carriers. Also provided herein include vaccine compositions comprising the multivalent carriers and related methods using the vaccine compositions in various therapeutic and prophylactic applications.
Disclosed are electrochemical systems that include an electrodialyzer and a vapor-fed CO2 reduction (CO2R) cell to capture and convert CO2 from ocean water. The electrodialyzer includes a stack of bipolar membrane electrodialysis (BPMED) cells between end electrodes. The electrodialzyer incorporates monovalent cation exchange membranes (M-CEMs) that prevent the transfer of multivalent cations between adjacent cell compartments, allowing continuous recirculation of electrolytes and solutions, and thus providing a safer and more scaling-free electrodialysis system. In some embodiments, the electrodialyzer may be configured to replace the water-splitting reaction at end electrodes with one-electron, reversible redox couples in solution at the electrodes. As a result, in the entire electrodialyzer stack, there is no bond-making, bond-breaking reactions and there is no gas generation, which significantly simplifies the cell design and improves operational safety. The systems provide a unique technological pathway for CO2 capture and conversion from ocean water with only electrochemical processes.
B01D 53/22 - SÉPARATION Épuration chimique ou biologique des gaz résiduaires, p.ex. gaz d'échappement des moteurs à combustion, fumées, vapeurs, gaz de combustion ou aérosols par diffusion
13.
ADENO-ASSOCIATED VIRUS COMPOSITIONS HAVING PREFERRED EXPRESSION LEVELS
Described herein are compositions and kits comprising recombinant adeno- associated viruses (rAAVs) with tropisms showing increased viral transduction in the CNS. The rAAV compositions described herein encapsidate a transgene, such as a therapeutic nucleic acid. Gene therapy using the rAAVs is described. Also described are methods of treating CNS-related diseases and conditions.
Systems and methods for measuring flow velocity of a fluid mixture in a lateral section of an oil/gas well are presented. The flow velocity is measured by tracking movement of particles and/or features in the fluid mixture via visible and/or infrared imaging sensors of a camera-based flow sensor (250). According to another aspect, the imaging sensors detect back-reflected light by the particles and/or features, the light emitted by illuminators (250b) in the visible and/ or infrared spectrum. According to yet another aspect, the particles are quantum dot illuminators injected into the fluid mixture, the flow velocity based on a time-of-flight of the quantum dots. The camera-based flow sensor may be rotatable to measure flow velocities at different angular positions of a pipe, rotation provided by rotation of an element of a mobile vessel to which the flow sensor is rigidly coupled.
E21B 47/113 - Localisation des fuites, intrusions ou mouvements du fluide utilisant un rayonnement lumineux
E21B 47/017 - Protection des instruments de mesure
E21B 47/11 - Localisation des fuites, intrusions ou mouvements du fluide utilisant la radioactivité
E21B 47/01 - Dispositifs pour supporter des instruments de mesure sur des trépans, des tubes, des tiges ou des câbles de forage; Protection des instruments de mesure dans les trous de forage contre la chaleur, les chocs, la pression ou similaire
G01P 5/20 - Mesure de la vitesse des fluides, p.ex. d'un courant atmosphérique; Mesure de la vitesse de corps, p.ex. navires, aéronefs, par rapport à des fluides en mesurant le temps mis par le fluide à parcourir une distance déterminée en utilisant des particules entraînées par un courant de fluide
15.
ANALYSIS OF TARGET MOLECULES WITHIN A SAMPLE VIA HYBRIDIZATION CHAIN REACTION
Methods of analysis of a sample using hybridization chain reaction (HCR) are provided herein. Some embodiments involve one, two, or all three of the following aspects: 1) repeated signal detection, 2) overlapping binding sites, and 3) catalytic reporter deposition (CARD). Compositions and kits relating to these are also provided. Some embodiments encompass a method for repeated signal detection with reporter-labeled HCR hairpins involving providing a sample possibly containing one or more targets as well as possibly other molecules that are not targets, providing one or more probe sets each comprising either: a) one or more HCR initiator-labeled probes, or b) one or more probe units each comprising two or more HCR fractional initiator probes, providing one or more HCR amplifiers (each labeled with one or more reporters), detecting one or more signals from one or more reporters. In some embodiments, a probe unit comprises two or more HCR fractional initiator probes, wherein an HCR fractional initiator probe comprises a target-binding region and a fractional initiator, wherein the target-binding regions within a probe unit are configured to bind to overlapping or non-overlapping binding sites on the target, and wherein the fractional initiators on the probes within each probe unit are configured to bind to overlapping or non-overlapping binding sites on an HCR hairpin. Some embodiments encompass a method for HCR-mediated catalytic reporter deposition (CARD) for signal detection with hapten-labeled HCR hairpins involving providing a sample possibly containing one or more targets as well as possibly other molecules that are not targets, providing one or more probe sets each comprising either: a) one or more HCR initiator-labeled probes, or b) one or more probe units each comprising two or more HCR fractional initiator probes, providing one or more HCR amplifiers (each labeled with one or more haptens), providing one or more anti-haptens labeled with one or more reporter entities, wherein the reporter entity is an enzyme that mediates CARD, providing one or more CARD-substrates leading to deposition of one or more reporters, and detecting one or more signals from one or more reporters.
A composition sensor (250) for measuring the composition of fluid mixtures (such as, for example, oil, water, and gas composition of an oil well) is presented. A system for gathering information about physical properties in a lateral section of a well, such as an oil well, is presented. The system comprises a mobile vessel (200) with the composition sensor (250) attached. The composition sensor (250) includes a plurality of high-brightness emission sources having respective spectrally narrow wavelength emission bands in the near-infrared region, e.g. in the region between 1400-1800 nm. The wavelength emission bands may overlap absorption wavelength bands of the composition. The wavelength emission bands are time multiplexed, and may be wavelength multiplexed, prior to emission through the fluid mixture. The composition sensor (250) includes a pair of opposing arms separated by a distance that defines a length of a measurement flow channel of the composition sensor. The arms may rotate to measure composition at different angular position of a pipe in a lateral section of an oil well.
E21B 49/00 - Test pour déterminer la nature des parois des trous de forage; Essais de couches; Procédés ou appareils pour prélever des échantillons du terrain ou de fluides en provenance des puits, spécialement adaptés au forage du sol ou aux puits
G01N 21/3504 - Couleur; Propriétés spectrales, c. à d. comparaison de l'effet du matériau sur la lumière pour plusieurs longueurs d'ondes ou plusieurs bandes de longueurs d'ondes différentes en recherchant l'effet relatif du matériau pour les longueurs d'ondes caractéristiques d'éléments ou de molécules spécifiques, p.ex. spectrométrie d'absorption atomique en utilisant la lumière infrarouge pour l'analyse des gaz, p.ex. analyse de mélanges de gaz
G01N 21/3577 - Couleur; Propriétés spectrales, c. à d. comparaison de l'effet du matériau sur la lumière pour plusieurs longueurs d'ondes ou plusieurs bandes de longueurs d'ondes différentes en recherchant l'effet relatif du matériau pour les longueurs d'ondes caractéristiques d'éléments ou de molécules spécifiques, p.ex. spectrométrie d'absorption atomique en utilisant la lumière infrarouge pour l'analyse de liquides, p.ex. l'eau polluée
G01N 21/359 - Couleur; Propriétés spectrales, c. à d. comparaison de l'effet du matériau sur la lumière pour plusieurs longueurs d'ondes ou plusieurs bandes de longueurs d'ondes différentes en recherchant l'effet relatif du matériau pour les longueurs d'ondes caractéristiques d'éléments ou de molécules spécifiques, p.ex. spectrométrie d'absorption atomique en utilisant la lumière infrarouge en utilisant la lumière de l'infrarouge proche
G01N 21/01 - Dispositions ou appareils pour faciliter la recherche optique
G01N 21/31 - Couleur; Propriétés spectrales, c. à d. comparaison de l'effet du matériau sur la lumière pour plusieurs longueurs d'ondes ou plusieurs bandes de longueurs d'ondes différentes en recherchant l'effet relatif du matériau pour les longueurs d'ondes caractéristiques d'éléments ou de molécules spécifiques, p.ex. spectrométrie d'absorption atomique
G01N 21/85 - Analyse des fluides ou solides granulés en mouvement
Provided are an apparatus and method for blood pressure measurement using an electroacoustic transducer in combination with a piezoelectric ultrasonic transducer. The apparatus and method can provide continuous, noninvasive blood pressure monitoring.
A61B 5/02 - Mesure du pouls, du rythme cardiaque, de la pression sanguine ou du débit sanguin; Détermination combinée du pouls, du rythme cardiaque, de la pression sanguine; Evaluation d'un état cardio-vasculaire non prévue ailleurs, p.ex. utilisant la combinaison de techniques prévues dans le présent groupe et des techniques d'électrocardiographie; Sondes cardiaques pour mesurer la pression sanguine
A61B 5/021 - Mesure de la pression dans le cœur ou dans les vaisseaux sanguins
A61B 5/022 - Mesure de la pression dans le cœur ou dans les vaisseaux sanguins par application d'une pression pour fermer les vaisseaux sanguins, p.ex. contre la peau; Ophtalmodynamomètres
A61B 5/0225 - Mesure de la pression dans le cœur ou dans les vaisseaux sanguins par application d'une pression pour fermer les vaisseaux sanguins, p.ex. contre la peau; Ophtalmodynamomètres la pression étant commandée par des signaux électriques, p.ex. dérivés des bruits de Korotkoff
A61B 5/023 - Mesure de la pression dans le cœur ou dans les vaisseaux sanguins par application d'une pression pour fermer les vaisseaux sanguins, p.ex. contre la peau; Ophtalmodynamomètres les transducteurs de pression comportant une colonne de liquide
A61K 31/428 - Thiazoles condensés avec des carbocycles
A61K 31/429 - Thiazoles condensés avec des systèmes hétérocycliques
A61K 31/4365 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p.ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle condensés en ortho ou en péri avec des systèmes hétérocycliques le système hétérocyclique ayant le soufre comme hétéro-atome du cycle, p.ex. ticlopidine
A61K 31/437 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p.ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle condensés en ortho ou en péri avec des systèmes hétérocycliques le système hétérocyclique contenant un cycle à cinq chaînons ayant l'azote comme hétéro-atome du cycle, p.ex. indolizine, bêta-carboline
A61K 31/496 - Pipérazines non condensées contenant d'autres hétérocycles, p.ex. rifampine, thiothixène
A61K 31/506 - Pyrimidines; Pyrimidines hydrogénées, p.ex. triméthoprime non condensées et contenant d'autres hétérocycles
A61P 35/02 - Agents anticancéreux spécifiques pour le traitement de la leucémie
C07D 417/14 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes de soufre et d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant au moins trois hétérocycles
Aspects of the invention include a method of producing a cement material comprising step of: first reacting a calcium-bearing starting material with a first acid to produce an aqueous first calcium salt; second reacting the aqueous first calcium salt with a second acid to produce a solid second calcium salt; wherein the second acid is different from the first acid and the second calcium salt is different from the first calcium salt; and thermally treating the second calcium salt to produce a first cement material. Preferably, but not necessarily, during the second reacting step, reaction between the first calcium salt and the second acid regenerates the first acid.
This disclosure provides novel broadly neutralizing anti-HIV antibodies and antigen-binding fragments thereof. The disclosed anti-HIV antibodies exhibited improved biophysical properties, e.g, reduced polyreactivity, prolonged half-life, while retaining broad and potent neutralization activity. The anti-HIV bNAb variants as disclosed constitute a novel therapeutic strategy for treating and/or preventing HIV infection.
The present invention relates to methods of treating immune disorders and/or inflammation using certain modulator compounds. For example, the present invention provides methods of treating immune and/or inflammatory disorders by administering a composition comprising a compound having the structure of Formula (I).
C07H 15/10 - Radicaux acycliques non substitués par des structures cycliques liés à un atome d'oxygène d'un radical saccharide contenant des liaisons non saturées carbone-carbone
A61K 31/351 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p.ex. fungichromine ayant des cycles à six chaînons avec un oxygène comme seul hétéro-atome d'un cycle non condensés avec un autre cycle
A61K 31/4025 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p.ex. guanéthidine ou rifamycines ayant des cycles à cinq chaînons avec un azote comme seul hétéro-atome d'un cycle, p.ex. sulpiride, succinimide, tolmétine, buflomédil non condensés et contenant d'autres hétérocycles, p.ex. cromakalim
A61K 31/4433 - Pyridines non condensées; Leurs dérivés hydrogénés contenant d'autres systèmes hétérocycliques contenant un cycle à six chaînons avec l'oxygène comme hétéro-atome du cycle
A61K 31/453 - Pipéridines non condensées, p.ex. pipérocaïne contenant d'autres systèmes hétérocycliques contenant un cycle à six chaînons avec l'oxygène comme hétéro-atome du cycle
A61K 31/7028 - Composés ayant des radicaux saccharide liés à des composés non-saccharide par des liaisons glycosidiques
A61K 31/7034 - Composés ayant des radicaux saccharide liés à des composés non-saccharide par des liaisons glycosidiques liés à un composé carbocyclique, p.ex. phloridzine
A61K 31/7056 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'azote comme hétéro-atome d'un cycle, p.ex. nucléosides, nucléotides contenant des cycles à cinq chaînons avec l'azote comme hétéro-atome d'un cycle
A61K 31/706 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'azote comme hétéro-atome d'un cycle, p.ex. nucléosides, nucléotides contenant des cycles à six chaînons avec l'azote comme hétéro-atome d'un cycle
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p.ex. agents antirhumatismaux; Médicaments anti-inflammatoires non stéroïdiens [AINS]
A61P 37/00 - Médicaments pour le traitement des troubles immunologiques ou allergiques
A61P 37/06 - Immunosuppresseurs, p.ex. médicaments pour le traitement du rejet de greffe
The invention relates to compounds of Formula I, and pharmaceutically acceptable salts thereof, and methods of making and using the same. The compounds of the invention are effective in inhibiting KRAS protein with a G12C mutation and are suitable for use in methods of treating cancers mediated, in whole or in part, by KRAS G12C mutation.
A61K 31/517 - Pyrimidines; Pyrimidines hydrogénées, p.ex. triméthoprime condensées en ortho ou en péri avec des systèmes carbocycliques, p.ex. quinazoline, périmidine
C07D 403/14 - Composés hétérocycliques contenant plusieurs hétérocycles, comportant des atomes d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant au moins trois hétérocycles
C07D 491/107 - Systèmes condensés en spiro avec un seul atome d'oxygène comme hétéro-atome du cycle contenant de l'oxygène
Provided are compositions and kits comprising recombinant adeno-associated viruses (rAAVs) with tropisms showing increased specificity and efficiency of viral transduction in targeted cell-types, for e.g., the brain and the liver. Therapeutic and biomedical research applications of the rAAVs are also described, including without limitation methods of discovering rAAVs using a multiplexed Cre recombination-based AAV targeted evolution (M- CREATE) method, and methods of treating various diseases and conditions by rAAV-mediated transgene therapy.
The present disclosure is directed to the integration of direct air capture of carbon dioxide with thermochemical water splitting, the latter optionally driven by solar energy. The disclosure is also directed to a process comprising extracting carbon dioxide from an air stream by contacting the air-stream with an alkali metal ion-transition metal oxide of empirical formula AxMO2 (0.1 < x ? 1), where A represents the alkali metal ion comprising sodium ion, potassium ion, or a combination thereof and M comprises iron, manganese, or a combination thereof to form a transition metal composition comprising an oxidized ion extracted-transition metal oxide.
B01D 53/14 - SÉPARATION Épuration chimique ou biologique des gaz résiduaires, p.ex. gaz d'échappement des moteurs à combustion, fumées, vapeurs, gaz de combustion ou aérosols par absorption
25.
SURFACE-IMMOBILIZED BISTABLE POLYNUCLEOTIDE DEVICES FOR THE SENSING AND QUANTIFICATION OF MOLECULAR EVENTS
Bistable devices are constructed using a polynucleotide platform for sensing molecular events such as binding or conformational changes of target molecules. Uses include measurement of target concentration, measuring the effect of environmental condition (such as heat, light, or pH) on the target, or screening a library for molecules that bind the target or modulate its biological function. Devices comprise three regions: a top lid, bottom lid, and flexible linker or hinge between them. A device has an open configuration in which the top and bottom lid are separated, and a closed configuration they are bound close together. Binding domains or variations of the target molecule are fixed to a device so that when the molecular event occurs, the device switches from open to closed, or vice versa, which generates a signal. Optimal device design is determined by the signal modality (optical or electronic) used to measure closure of surface-immobilized devices
C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismes; Compositions à cet effet; Procédés pour préparer ces compositions faisant intervenir des acides nucléiques
The present disclosure describes compounds of formulas (I)-(V) and methods of making the same. The compounds of the present disclosure are useful as inhibitors of PRMT5 activity and in methods of treating cancers and other diseases.
A61P 35/02 - Agents anticancéreux spécifiques pour le traitement de la leucémie
C07D 519/00 - Composés hétérocycliques contenant plusieurs systèmes de plusieurs hétérocycles déterminants condensés entre eux ou condensés avec un système carbocyclique commun non prévus dans les groupes ou
27.
SYSTEMS, DEVICES, AND METHODS RELATING TO THE MANUFACTURE OF IMPLANTABLE PROSTHETIC VALVES
Improved prosthetic valves, their methods of manufacture, and systems and devices for manufacturing the valves are described. The prosthetic valves can be configured for transcatheter implantation. The prosthetic valves can have artificial leaflets. The prosthetic valves can be manufactured in numerous ways, such as by polymeric dipping processes and/or electrospinning. Sponge-like polymers for valves and other medical devices are also disclosed.
A61F 2/00 - Filtres implantables dans les vaisseaux sanguins; Prothèses, c.-à-d. éléments de substitution ou de remplacement pour des parties du corps; Appareils pour les assujettir au corps; Dispositifs maintenant le passage ou évitant l'affaissement de structures corporelles tubulaires, p.ex. stents
This disclosure provides HIV immunogens and use thereof for generating an immune response in a subject. Also disclosed is a method of isolating anti-HIV antibodies and use thereof. This disclosure further provides a method for treating or preventing a human immunodeficiency type 1 (HIV-1) infection in a subject using the disclosed HIV immunogens and/or antibodies.
A61K 31/437 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p.ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle condensés en ortho ou en péri avec des systèmes hétérocycliques le système hétérocyclique contenant un cycle à cinq chaînons ayant l'azote comme hétéro-atome du cycle, p.ex. indolizine, bêta-carboline
A61K 31/4985 - Pyrazines ou pipérazines condensées en ortho ou en péri avec des systèmes hétérocycliques
Tumor-specific T cell receptor (TCR) gene transfer enables specific and potent immune targeting of tumor antigens. The canonical cancer-testis antigen, NY-ESO-1, is not expressed in normal tissues but is aberrantly expressed across a broad array of cancer types. It has also been targeted with A2-restricted TCR gene therapy without adverse events or notable side effects. To enable the targeting of NY-ESO-1 in a broader array of HLA haplotypes, we isolated TCRs specific for NY-ESO-1 epitopes presented by four MHC molecules: HLA-A2, -B07, -B18, and -C03. Using these TCRs, we have developed an approach to extend TCR gene therapies targeting NY-ESO-1 to patient populations beyond those expressing HLA-A2.
A61K 47/64 - Conjugués médicament-peptide, médicament-protéine ou médicament-acide polyaminé, c. à d. l’agent de modification étant un peptide, une protéine ou un acide polyaminé lié par covalence ou complexé à un agent thérapeutiquement actif
A61K 47/65 - Séquences de liaison, liants ou bras-espaceurs peptidiques, p.ex. séquences de liaison peptidiques vulnérable aux protéases
Described herein are compositions and kits comprising recombinant adeno-associated viruses (rAAVs) with tropisms showing increased specificity and efficiency of viral transduction in targeted cell-types, for e.g., the brain, and lung. The rAAV compositions described herein also have tropisms showing decreased specificity and decreased efficiency of viral transduction in an off-target cell type, for e.g., the liver. The rAAV compositions described herein encapsidate a transgene, such a therapeutic nucleic acid. Upon systemic delivery to a subject, the rAAV is capable of increased specificity and increased transduction of the transgene in a target cell-type, as compared to a parental or reference AAV.
THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS (USA)
Inventeur(s)
Grubbs, Robert H.
Schwartz, Daniel M.
Abrégé
Disclosed herein include methods, kits, formulations, and compositions for increasing choroidal or retinal perfusion or promoting non-leaking or minimally-leaking choroidal or retinal revascularization in a subject in need thereof. An effective amount of an angiogenesis factor (e.g., a pro-angiogenic factor and/or a vascular maturation factor) can be administered to the subject.
C07D 401/14 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant au moins trois hétérocycles
A61K 31/506 - Pyrimidines; Pyrimidines hydrogénées, p.ex. triméthoprime non condensées et contenant d'autres hétérocycles
A61K 31/5386 - 1,4-Oxazines, p.ex. morpholine condensées en spiro ou formant une partie de systèmes cycliques pontés
The present application discloses nanoparticles carrying therapeutic agents, including chemotherapeutic agents, and targeting ligands suitable for delivering these therapeutic agents through the blood brain barrier and methods of using these patients on those patients in need of such treatment.
A61K 49/18 - Préparations de contraste pour la résonance magnétique nucléaire (RMN); Préparations de contraste pour l'imagerie par résonance magnétique (IRM) caractérisées par un aspect physique particulier, p.ex. émulsions, microcapsules, liposomes
35.
EYE TREATMENT DEVICE HAVINGA THERAPEUTIC LIQUID STORAGE CHAMBER AND A REPLENISHMENT CHAMBER
An eye treatment apparatus is described. The apparatus includes an annular body that has a hollow optical zone in its center. An inner perimeter of the annular body surrounds the optical zone. The inner perimeter has a diameter that corresponds to a diameter of the eye's cornea. An outer perimeter of the annular body has a diameter such that the annular body can extend to underneath the eye lid in an open eye position when the eye treatment apparatus is in operation. In this way, the apparatus can be worn on the eye, where the hollow optical zone substantially corresponds to the cornea and does not interfere with the field of vision. The annular body also includes a storage chamber that stores therapeutic liquid for an eye. An outlet is coupled with the storage chamber such that, in operation, the therapeutic liquid can be dispensed to the eye.
A61F 9/00 - Procédés ou dispositifs pour le traitement des yeux; Dispositifs pour mettre en place des verres de contact; Dispositifs pour corriger le strabisme; Appareils pour guider les aveugles; Dispositifs protecteurs pour les yeux, portés sur le corps ou dans la main
A61M 37/00 - Autres appareils pour introduire des agents dans le corps; Percutanisation, c. à d. introduction de médicaments dans le corps par diffusion à travers la peau
36.
FABRICATION AND DESIGN OF COMPOSITES WITH ARCHITECTED LAYERS
In an aspect, a composite material system comprises: a structure having an architected three-dimensional geometry; wherein said three-dimensional geometry is monolithic and deterministic; and a matrix phase; wherein said matrix phase at least partially infiltrates said structure. In some embodiments, the three-dimensional geometry is a nano- or micro- architected three-dimensional geometry.
In an aspect, provided herein are methods for producing sulfuric acid and hydrogen gas, the methods comprising steps of: providing sulfur dioxide formed by thermal conversion of a sulfur-containing species; electrochemically oxidizing said sulfur dioxide to sulfuric acid in the presence of water; and electrochemically forming hydrogen gas via a reduction reaction. In some embodiments, the methods comprise a step of thermally converting said sulfur-containing species to said sulfur dioxide. Systems configured to perform these methods are also disclosed herein. Also provided herein are methods and systems for producing sulfuric acid and hydrogen gas by electrochemically forming the sulfuric acid and the hydrogen gas in a mixture comprising a sulfur material, a supporting acid, and water. Also provided herein are methods and systems for producing a cement material.
H01M 8/0656 - Combinaison d’éléments à combustible avec des moyens de production de réactifs ou pour le traitement de résidus avec des moyens de production des réactifs gazeux par des moyens électrochimiques
C01B 17/54 - Préparation de l'anhydride sulfureux en brûlant du soufre élémentaire
C04B 2/10 - Préchauffage, cuisson, calcination ou refroidissement
The present disclosure is directed at methods of forming an N-Si silyl bond, the method comprising contacting an organic substrate comprising an aromatic amine having at least one N- H bond with a mixture comprising of (a) at least one hydrosilane or hydrosiloxane and (b) at least one hydroxide or alkoxide, under conditions sufficient to form the N-Si bond. The disclosure is further directed to the compositions involved in these methods and the products that result therefrom.
The present invention relates to methods of treating bacterial infections and cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of at least one compound provided herein. Also provided are methods of inhibiting dolichyl-phosphate N-acetylglucosaminephosphotransferase (DPAGT1) in an individual in need thereof, comprising administering to the individual a therapeutically effective amount of any of the compounds or compositions described herein.
C07H 19/073 - Radicaux pyrimidine avec un désoxy-2 ribosyle comme radical saccharide
A61K 31/7072 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'azote comme hétéro-atome d'un cycle, p.ex. nucléosides, nucléotides contenant des cycles à six chaînons avec l'azote comme hétéro-atome d'un cycle contenant des pyrimidines condensées ou non-condensées ayant des groupes oxo liés directement au cycle pyrimidine, p.ex. cytidine, acide cytidylique ayant deux groupes oxo liés directement au cycle pyrimidine, p.ex. uridine, acide uridylique, thymidine, zidovudine
A61P 31/00 - Agents anti-infectieux, c. à d. antibiotiques, antiseptiques, chimiothérapeutiques
Improved prosthetic heart valves, their methods of manufacture, and systems and devices for manufacturing the valves are described. The prosthetic heart valves can be configured for transcatheter implantation. The prosthetic heart valves can have artificial leaflets. The prosthetic heart valves can be manufactured in numerous ways, such as by polymeric dipping processes.
A61F 2/00 - Filtres implantables dans les vaisseaux sanguins; Prothèses, c.-à-d. éléments de substitution ou de remplacement pour des parties du corps; Appareils pour les assujettir au corps; Dispositifs maintenant le passage ou évitant l'affaissement de structures corporelles tubulaires, p.ex. stents
WIRELESS VECTOR KINEMATIC SENSING OF LINEAR AND ANGULAR, VELOCITY AND ACCELERATION, AND POSITION AND ORIENTATION VIA WEAKLY-COUPLED QUASISTATIC MAGNETIC FIELDS
Range and orientation of a transmitter and a receiver are found by detecting the magnetoquasistatic field couplings between coils at the transmitter and receiver. Sum functions and ratio functions are calculated for each of the unique magnetoquasistatic field couplings between the transmitter and the receiver. The sum and ratio functions are inverted to determine the drift-free range and orientation. Linear and angular velocity and acceleration are calculated by applying a filter to reduce noise, and then taking the corresponding derivatives.
G01S 5/02 - Localisation par coordination de plusieurs déterminations de direction ou de ligne de position; Localisation par coordination de plusieurs déterminations de distance utilisant les ondes radioélectriques
G01C 21/16 - Navigation; Instruments de navigation non prévus dans les groupes en utilisant des mesures de la vitesse ou de l'accélération exécutées à bord de l'objet navigant; Navigation à l'estime en intégrant l'accélération ou la vitesse, c. à d. navigation par inertie
42.
MULTIPLEX LABELING OF MOLECULES BY SEQUENTIAL HYBRIDIZATION BARCODING WITH RAPID SWITCHING AND REHYBRIDZATION OF PROBES
The present invention, among other things, provides technologies for detecting and/or quantifying nucleic acids in cells, tissues, organs or organisms. Through sequential barcoding, the present invention provides methods for high-throughput profiling of a large number of targets, such as transcripts and/or DNA loci. In some embodiments, nucleic acid probes include a signal moiety connected with a binding sequence via a cleavable linker.
Cascaded metasurfaces can control the phase, amplitude and polarization of an electromagnetic beam, shaping it in three dimensional configuration not achievable with other methods. Each cascaded metasurface has dielectric or metallic scatterers arranged in a period array. The shape of the scatterers determines the three dimensional configuration of the output beam and is determined with iterative calculations through computational simulations.
G03F 7/00 - Production par voie photomécanique, p.ex. photolithographique, de surfaces texturées, p.ex. surfaces imprimées; Matériaux à cet effet, p.ex. comportant des photoréserves; Appareillages spécialement adaptés à cet effet
44.
RUGGEDIZED BUOYANT MEMORY MODULES FOR DATA LOGGING AND DELIVERY SYSTEM USING FLUID FLOW IN OIL AND GAS WELLS
Systems and methods for delivering detailed information about physical properties, including inflow data, in a downhole of a well to the surface without the need of providing cabling to the downhole are presented. Such information can be based on data captured by sensors placed within the downhole of the well, and subsequently stored into memory of ruggedized buoyant memory modules (RBMMs) that are physically injected into the fluid flow of the well. The RBMMs use the flow of the fluid inside of the well to deliver the data to a location where the data can be extracted. Data stored in the RBMMs can be extracted either directly from the RBMMs or remotely via, for example, a wireless interface.
E21B 47/12 - Moyens pour la transmission de signaux de mesure ou signaux de commande du puits vers la surface, ou de la surface vers le puits, p.ex. pour la diagraphie pendant le forage
E21B 43/30 - Disposition particulière des puits, p.ex. disposition rendant optimum l'espacement des puits
E21B 47/01 - Dispositifs pour supporter des instruments de mesure sur des trépans, des tubes, des tiges ou des câbles de forage; Protection des instruments de mesure dans les trous de forage contre la chaleur, les chocs, la pression ou similaire
Systems and methods relate to arranging atoms into 1D and/or 2D arrays; exciting the atoms into Rydberg states and evolving the array of atoms, for example, using laser manipulation techniques and high-fidelity laser systems described herein; and observing the resulting final state. In addition, refinements can be made, such as providing high fidelity and coherent control of the assembled array of atoms. Exemplary problems can be solved using the systems and methods for arrangement and control of atoms.
The present disclosure provides methods and compositions for the prevention, amelioration, or alleviation of one or more neurological disorders associated with microbially- induced amyloid formation. Methods of inhibiting, ameliorating, reducing the likelihood, delaying the onset of, treating, or preventing an amyloid disorder are disclosed. Methods of identifying compounds capable of inhibiting the formation of microbially-induced amyloid fibrils are disclosed.
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p.ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
Novel monolithic cyclical reflective spatial heterodyne spectrometers (CRSHS) are presented. Monolithic CRSHS in accordance with the invention have a single frame wherein a flat mirror, roof mirror, and symmetric grating are affixed. The invention contains only fixed parts; the flat mirror, roof mirror, and symmetric grating do not move in relation to the frame. Compared to conventional CRSHS known in the art, the present invention enables much smaller and lighter CRSHS, requires less time and skill for maintenance, and is a better economic option. The disclosed invention may include fixed field-widening optical elements or a fiber-fed assembly.
An enhanced stethoscope device and method for operating the enhanced stethoscope are provided. The enhanced stethoscope device generally operates by providing stethoscope sensors, ultrasonic sensors, and other sensors to obtain a series of measurements about a subject. The series of measurements may be correlated, such as by machine learning, to extract clinically relevant information. Also described are systems and methods for ultrasonic beamsteering by interference of an audio signal with an ultrasonic signal.
The present invention, among other things, provides technologies for detecting and/or quantifying nucleic acids in cells, tissues, organs or organisms. Pre-designed barcodes are associated specific molecular targets through sequential hybridization experiments. A pseudo¬ color based barcoding scheme is developed to overcome limitations in the previous generation of the technology such as lack of visual signals that can be associated with the probes or small internal within cell when carrying out in situ experiments.. The current method can be applied to both in vitro and in situ analysis. According to the method, each barcoding round comprises multiple serial hybridizations where a small number of colored signals (that are associated with probes) are used in each hybridization experiment within a serial hybridization round. Images from each serial hybridization experiment within the same serial hybridization round are combined to form a composite image for each barcoding round. In each barcoding round, the same set of molecular targets are analyzed. After all barcoding rounds are completed, associated of the barcode with these molecular targets is completed.
C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismes; Compositions à cet effet; Procédés pour préparer ces compositions faisant intervenir des acides nucléiques
The present disclosure relates to methods and compositions involving HCR reactions that involve initiators that are split into two or more parts. Effective HCR is dependent upon two or more of these split initiators being brought into proximity (e.g., via binding events mediated by a target) such that a full initiator is formed that is capable of triggering HCR signal amplification.
C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismes; Compositions à cet effet; Procédés pour préparer ces compositions faisant intervenir des acides nucléiques
C07H 21/02 - Composés contenant au moins deux unités mononucléotide comportant chacune des groupes phosphate ou polyphosphate distincts liés aux radicaux saccharide des groupes nucléoside, p.ex. acides nucléiques avec le ribosyle comme radical saccharide
The present invention is directed to compositions for silylating organic substrates containing C-H or O-H bonds, especially heteroaromatic substrates. The compositions are derived from the preconditioning of mixtures of hydrosilanes or organodisilanes with bases, including metal hydroxide and metal alkoxide bases. In some embodiments, the preconditioning results in the formation of reactive silicon hydride species.
Features for rechargeable lithium ion batteries, the batteries optionally employing vertically aligned carbon nanotube scaffolding, are described. Methods of manufacture and a solid polymer electrolyte are described for 3-dimensional battery architectures using the vertically aligned carbon nanotubes. Poly(ethylene)oxide bis(azide) and graphene poly(lactic acid) composite coatings are also described for use in such batteries or others.
H01M 10/0525 - Batteries du type "rocking chair" ou "fauteuil à bascule", p.ex. batteries à insertion ou intercalation de lithium dans les deux électrodes; Batteries à l'ion lithium
H01M 4/525 - Emploi de substances spécifiées comme matériaux actifs, masses actives, liquides actifs d'oxydes ou d'hydroxydes inorganiques de nickel, de cobalt ou de fer d'oxydes ou d'hydroxydes mixtes contenant du fer, du cobalt ou du nickel pour insérer ou intercaler des métaux légers, p.ex. LiNiO2, LiCoO2 ou LiCoOxFy
H01M 10/0561 - Accumulateurs à électrolyte non aqueux caractérisés par les matériaux utilisés comme électrolytes, p.ex. électrolytes mixtes inorganiques/organiques l'électrolyte étant constitué uniquement de matériaux inorganiques
H01G 11/56 - Condensateurs hybrides, c. à d. ayant des électrodes positive et négative différentes; Condensateurs électriques à double couche [EDL]; Procédés de fabrication desdits condensateurs ou de leurs composants Électrolytes Électrolytes solides, p.ex. gels; Additifs pour ceux-ci
54.
TARGETING PEPTIDES FOR DIRECTING ADENO-ASSOCIATED VIRUSES (AAVS)
Disclosed herein are peptide sequences capable of directing adeno-associated viruses (AAV) to target specific environments, for example the nervous system and the heart, in a subject. Also disclosed are AAVs having non-naturally occurring capsid proteins comprising the disclosed peptide sequences, and methods of using the AAVs to treat diseases.
Described herein are associative polymers capable of controlling a physical and/or chemical property of non-polar compositions that can be used when the non-polar composition is in a flow, and related compositions, methods and systems. Associative polymers herein described have a non-polar backbone with a longest span having a molecular weight that remains substantially unchanged under the flow conditions and functional groups presented at ends of the non-polar backbone, with a number of the functional groups presented at the ends of the non-polar backbone formed by associative functional groups capable of undergoing an associative interaction with another associative functional group with an association constant (k) such that the strength of each associative interaction is less than the strength of a covalent bond between atoms and in particular less than the strength of a covalent bond between backbone atoms.
C10L 1/04 - Combustibles carbonés liquides à base essentielle de mélanges d'hydrocarbures
C08L 101/12 - Compositions contenant des composés macromoléculaires non spécifiés caractérisées par des propriétés physiques, p.ex. anisotropie, viscosité ou conductivité électrique
C10L 1/06 - Combustibles carbonés liquides à base essentielle de mélanges d'hydrocarbures pour allumage par bougie
Compositions and methods for isolating patient -derived antigen-specific T cells include an antigen complex having a polynucleotide barcoded nanoparticle sorting agent complexed with a peptide-loaded streptavidin major histocompatability complex (MHC) tetramer, the barcoding technology allowing for high fidelity screening of a library of the antigen complexes to readily isolate and identify antigen-specific T cells.
G01N 33/569 - Tests immunologiques; Tests faisant intervenir la formation de liaisons biospécifiques; Matériaux à cet effet pour micro-organismes, p.ex. protozoaires, bactéries, virus
G01N 33/52 - Utilisation de composés ou de compositions pour des recherches colorimétriques, spectrophotométriques ou fluorométriques, p.ex. utilisation de bandes de papier indicateur
G01N 33/53 - Tests immunologiques; Tests faisant intervenir la formation de liaisons biospécifiques; Matériaux à cet effet
G01N 33/543 - Tests immunologiques; Tests faisant intervenir la formation de liaisons biospécifiques; Matériaux à cet effet avec un support insoluble pour l'immobilisation de composés immunochimiques
57.
HETEROAROMATIC SILICON-FLUORIDE-ACCEPTORS USEFUL FOR 18F LABELING OF MOLECULES AND BIOMOLECULES, AND METHODS OF PREPARING SAME
The present invention includes novel compounds and compositions including heteroaromatic Silicon-Fluoride-Acceptors, which are useful for PET scanning. The present invention further includes a novel method of 18F imaging for PET scanning, the method comprising the preparation of conjugates and bioconjugates of biological ligands of interest with heteroaromatic silicon-fluoride-acceptors. In one embodiment the invention is practiced in the form of a kit.
This invention provides efficient and scalable enantioselective methods that yield 2-alkyl-2-allylcycloalkyanone compounds with quaternary stereogenic centers. Methods include the method for the preparation of a compound of formula (I), comprising treating a compound of formula (II) or (III), with a palladium (II) catalyst under alkylation conditions.
C07C 49/303 - Composés saturés comportant des groupes cétone liés à des cycles à un cycle à six chaînons
C07C 49/307 - Composés saturés comportant des groupes cétone liés à des cycles à un cycle de sept à douze chaînons
C07D 211/70 - Composés hétérocycliques contenant des cycles pyridiques hydrogénés, non condensés avec d'autres cycles avec uniquement des atomes d'hydrogène et de carbone liés directement à l'atome d'azote du cycle comportant une liaison double entre chaînons cycliques ou entre chaînon cyclique et chaînon non cyclique avec uniquement des atomes d'hydrogène, des radicaux hydrocarbonés ou des radicaux hydrocarbonés substitués, liés directement aux atomes de carbone du cycle
Disclosed herein are methods and devices for rapid assessment of whether a microorganism present in a sample is susceptible or resistant to a treatment.
C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismes; Compositions à cet effet; Procédés pour préparer ces compositions faisant intervenir des acides nucléiques
C12Q 1/70 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismes; Compositions à cet effet; Procédés pour préparer ces compositions faisant intervenir des virus ou des bactériophages
60.
COMPOSITIONS AND METHODS COMPRISING BACTERIA FOR IMPROVING BEHAVIOR IN NEURODEVELOPMENTAL DISORDERS
Some embodiments include bacterial species for use in treatment of one or more autism spectrum disorder (ASD), and/or schizophrenia symptoms in a subject in need thereof. The subject in need thereof can have a gut micro biota signature characteristic of an adult. The bacterial species can include Bacleroides (e.g., B.fragilis, B. thetaiomtaomicron, and/or B. vulgatus), and/or Enterococcus (e.g., E. faecaiis, E. faecium, E. hirae, E. avium, E. durans, E. gallinarum, or E. casseliflavus). Upon treatment, one or more ASD-related behaviors can be improved in the subject.
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p.ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
61.
COMPOSITIONS AND METHODS COMPRISING BACTERIA FOR IMPROVING BEHAVIOR IN NEURODEVELOPMENTAL DISORDERS
Some embodiments include bacterial species for use in treatment of one or more autism spectrum disorder (ASD), and/or schizophrenia symptoms in a subject in need thereof. The bacterial species can include Bacteroides (e.g., B. fragilis, B. thetaiomlaomicron, and/or B. vulgatus), and/or Enterococcus (e.g., E. faecalis, E.faecium, E. hirae, E. avium, E. durans, E. gallinarum, or E. casseliflavus). Upon treatment, one or more ASD-related behaviors can be improved in the subject.
The present invention describes chemical systems and methods for silylating aromatic organic substrates, said system or method comprising or consisting essentially of a mixture of (a) at least one organosilane and (b) at least one strong base, the definition of strong base now also including hydroxide, especially KOH, said system being preferably, but not necessarily substantially free of a transition-metal compound, and said methods comprising contacting a quantity of the organic substrate with a mixture of (a) at least one organosilane and (b) at least one strong base, under conditions sufficient to silylate the aromatic substrate; wherein said system is substantially free of a transition-metal compound.
C07D 333/50 - Composés hétérocycliques contenant des cycles à cinq chaînons comportant un atome de soufre comme unique hétéro-atome du cycle condensés avec des carbocycles ou avec des systèmes carbocycliques
Described herein are methods of delivering a nanoparticle to the brain of a subject by administering to the subject a nanoparticle having a nanoparticle core and a targeting agent. A variety of targeting agents may serve to promote delivery of the described nanoparticle. For example, the targeting agent may include a ligand specific for a receptor expressed by brain endothelial cells and a linker that connects the ligand to the external surface of the nanoparticle core. Additionally, the linker can promote disassociation of the ligand from the nanoparticle when inside a cell.
A61K 47/69 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. les supports ou les additifs inertes; Agents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p.ex. conjugués polymère-médicament le conjugué étant caractérisé par sa forme physique ou sa forme galénique, p.ex. émulsion, particule, complexe d’inclusion, stent ou kit
A61K 31/4045 - Indole-alkylamines; Leurs amides, p.ex. sérotonine, mélatonine
A61K 47/34 - Composés macromoléculaires obtenus par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone, p.ex. polyesters, acides polyaminés, polysiloxanes, polyphosphazines, copolymères de polyalkylène glycol o
Described herein are methods of delivering a nanoparticle to the brain of a subject by administering to the subject a nanoparticle having a nanoparticle core and a targeting agent. A variety of targeting agents may serve to promote delivery of the described nanoparticle. For example, the targeting agent may include a ligand specific for a receptor expressed by brain endothelial cells and a linker that connects the ligand to the external surface of the nanoparticle core. Additionally, the linker can promote disassociation of the ligand from the nanoparticle when inside a cell.
A61K 47/59 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. les supports ou les additifs inertes; Agents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p.ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique macromoléculaire, p.ex. une molécule oligomérique, polymérique ou dendrimérique obtenu par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone, p.ex. polyurées ou polyuréthanes
65.
METHOD OF DELIVERING THERAPEUTICS AND IMAGING AGENTS BY NANOPARTICLES THAT CROSS THE BLOOD BRAIN BARRIER
Described herein are methods of delivering a nanoparticle to the brain of a subject by administering to the subject a nanoparticle having a nanoparticle core and a targeting agent. A variety of targeting agents may serve to promote delivery of the described nanoparticle. For example, the targeting agent may include a ligand specific for a receptor expressed by brain endothelial cells and a linker that connects the ligand to the external surface of the nanoparticle core. Additionally, the linker can promote disassociation of the ligand from the nanoparticle when inside a cell.
A61K 47/69 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. les supports ou les additifs inertes; Agents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p.ex. conjugués polymère-médicament le conjugué étant caractérisé par sa forme physique ou sa forme galénique, p.ex. émulsion, particule, complexe d’inclusion, stent ou kit
A61K 31/4045 - Indole-alkylamines; Leurs amides, p.ex. sérotonine, mélatonine
A61K 47/34 - Composés macromoléculaires obtenus par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone, p.ex. polyesters, acides polyaminés, polysiloxanes, polyphosphazines, copolymères de polyalkylène glycol o
The present invention, among other things, provides technologies for detecting and/or quantifying nucleic acids in cells, tissues, organs or organisms. In some embodiments, through sequential barcoding, the present invention provides methods for high-throughput profiling of a large number of targets, such as transcripts and/or DNA loci.
C12Q 1/6818 - Tests d’hybridation caractérisés par les moyens de détection impliquant l’interaction de plusieurs marqueurs, p.ex. transfert d’énergie de résonance
C12Q 1/6806 - Préparation d’acides nucléiques pour analyse, p.ex. pour test de réaction en chaîne par polymérase [PCR]
C12Q 1/6816 - Tests d’hybridation caractérisés par les moyens de détection
C40B 30/04 - Procédés de criblage des bibliothèques en mesurant l'aptitude spécifique à se lier à une molécule cible, p.ex. liaison anticorps-antigène, liaison récepteur-ligand
C40B 70/00 - CHIMIE COMBINATOIRE; BIBLIOTHÈQUES, p.ex. CHIMIOTHÈQUES Étiquettes ["tags"] ou marqueurs ["labels"] spécialement adaptés à la chimie combinatoire ou aux chimiothèques, p.ex. "tags" fluorescents ou codes-barres
Methods are provided herein for preventing, delaying the onset of or reducing the progression of colorectal tumorigenesis in a subject identified as at risk of colorectal tumorigenesis, comprising adjusting the composition of gut microbiota in the subject via administering to the subject a composition comprising Bacteroides bacteria or administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising zwitterionic polysaccharide (ZPS). In another aspect, methods are provided for treating or ameliorating a colorectal cancer in a subject, comprising adjusting the composition of gut microbiota in the subject having the colorectal cancer. In a further aspect, methods are provided for relieving gastrointestinal (GI) distress of a subject having a colorectal condition, comprising: determining the colorectal condition of the subject; and relieving GI distress in the subject by adjusting the composition of gut microbiota in the subject.
A61K 31/59 - Composés contenant le système cyclique du 9,10-séco-cyclopenta[a]hydrophénanthrène
A61K 31/715 - Polysaccharides, c. à d. ayant plus de cinq radicaux saccharide liés les uns aux autres par des liaisons glycosidiques; Leurs dérivés, p.ex. éthers, esters
C07H 13/00 - Composés contenant des radicaux saccharide estérifiés soit par l'acide carbonique ou ses dérivés, soit par des acides organiques, p.ex. acides phosphoniques
G01N 33/00 - Recherche ou analyse des matériaux par des méthodes spécifiques non couvertes par les groupes
68.
ASSOCIATIVE POLYMERS AND RELATED COMPOSITIONS, METHODS AND SYSTEMS
Described herein are associative polymers capable of controlling one or more physical and/or chemical properties of non-polar compositions and related compositions, methods and systems. The non-polar composition comprises a host composition having a dielectric constant equal to or less than about 5, and at least one associative polymer which is soluble in the host composition in a concentration between from about 0.1c* to about 10c* and comprises a linear, branched, or hyperbranched polymer backbone having at least two ends and a functional group presented at two or more ends of the at least two ends of the backbone, and wherein the linear, branched, or hyperbranched polymer backbone is substantially soluble in a non-polar composition, and the functional group is capable of undergoing an associative interaction with another functional group with an association constant (k) of from 0.1<1ogiok< 1 8
C08L 101/02 - Compositions contenant des composés macromoléculaires non spécifiés caractérisées par la présence de groupes déterminés
C08F 265/00 - Composés macromoléculaires obtenus par polymérisation de monomères sur des polymères d'acides monocarboxyliques non saturés ou de leurs dérivés tels que définis dans le groupe
C08F 290/00 - Composés macromoléculaires obtenus par polymérisation de monomères sur des polymères modifiés par introduction de groupes aliphatiques non saturés terminaux ou latéraux
C08G 83/00 - Composés macromoléculaires non prévus dans les groupes
C08L 51/00 - Compositions contenant des polymères greffés dans lesquels le composant greffé est obtenu par des réactions faisant intervenir uniquement des liaisons non saturées carbone-carbone; Compositions contenant des dérivés de tels polymères
69.
CROSSLINKED POLYMER ELECTROLYTE FORMED FROM TELECHELIC PRECURSOR POLYMERS
A composite electrolyte can include a crosslinked polymer formed from telechelic precursor polymers having at least two photoactivatable end functional groups and a molecular weight before crosslinking of between about 1,000 and 1,000,000 Daltons (Da); and a lithium (Li) salt. Electrochemical cells and batteries including such electrolytes are also disclosed, along with various methods of manufacture.
The present invention relates to anti-HIV antibodies. Also disclosed are related methods and compositions. HIV causes acquired immunodeficiency syndrome (AIDS), a condition in humans characterized by clinical features including wasting syndromes, central nervous system degeneration and profound immunosuppression that results in life-threatening opportunistic infections and malignancies. Since its discovery in 1981, HIV type 1 (HIV -1) has led to the death of at least 25 million people worldwide.
G01N 33/564 - Tests immunologiques; Tests faisant intervenir la formation de liaisons biospécifiques; Matériaux à cet effet pour complexes immunologiques préexistants ou maladies auto-immunes
71.
DIAGNOSIS AND TREATMENT OF AUTISM SPECTRUM DISORDER
Disclosed herein are compositions, systems, and methods for diagnosing and treatment of subjects suffering from anxiety, autism spectrum disorder (ASD), or a pathological condition with one or more of the symptoms of ASD.
A61K 35/12 - Substances provenant de mammifères; Compositions comprenant des tissus ou des cellules non spécifiés; Compositions comprenant des cellules souches non embryonnaires; Cellules génétiquement modifiées
A sensor with an inner enclosure, an outer enclosure and a first layer between an outer surface of the inner enclosure and an inner surface of the outer enclosure is described. The sensor further includes an energy harvesting tool and an internal source of power. The energy harvesting tool is configured to harvest mechanical and/or thermal energy and/or sunlight from ambient resources and store the harvested energy in the internal source of power.
G01D 11/00 - MESURE NON SPÉCIALEMENT ADAPTÉE À UNE VARIABLE PARTICULIÈRE; DISPOSITIONS NON COUVERTES PAR UNE SEULE DES AUTRES SOUS-CLASSES POUR MESURER PLUSIEURS VARIABLES; APPAREILS COMPTEURS À TARIFS; DISPOSITIONS POUR LE TRANSFERT OU LA TRANSDUCTION DE MESURE NON SPÉCIALEMENT ADAPTÉES À UNE VARIABLE PARTICULIÈRE; MESURES OU TESTS NON PRÉVUS AILLEURS - Parties constitutives des dispositions pour la mesure qui ne sont pas spécialement adaptées à une variable particulière
H04W 84/18 - Réseaux auto-organisés, p.ex. réseaux ad hoc ou réseaux de détection
G01V 9/00 - Prospection ou détection par des procédés non prévus dans les groupes
H01J 49/00 - Spectromètres pour particules ou tubes séparateurs de particules
H01M 10/0525 - Batteries du type "rocking chair" ou "fauteuil à bascule", p.ex. batteries à insertion ou intercalation de lithium dans les deux électrodes; Batteries à l'ion lithium
G01J 3/44 - Spectrométrie Raman; Spectrométrie par diffusion
74.
AKT-SPECIFIC CAPTURE AGENTS, COMPOSITIONS, AND METHODS OF USING AND MAKING
The present application provides stable peptide-based Akt capture agents and the use thereof as detection, diagnosis, and treatment agents. The application further provides novel methods of developing stable peptide-based capture agents, including Akt capture agents, using iterative on-bead in situ click chemistry.
G01N 33/68 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des protéines, peptides ou amino-acides
G01N 33/53 - Tests immunologiques; Tests faisant intervenir la formation de liaisons biospécifiques; Matériaux à cet effet
G01N 33/58 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des substances marquées
75.
HUMAN IMMUNODEFICIENCY VIRUS NEUTRALIZING ANTIBODIES AND METHODS OF USE THEREOF
The invention provides broadly neutralizing antibodies directed to epitopes of Human Immunodeficiency Virus, or HIV. The invention further provides compositions containing HIV antibodies used for prophylaxis, and methods for diagnosis and treatment of HIV infection.
A61P 31/18 - Antiviraux pour le traitement des virus ARN du HIV
C07H 21/04 - Composés contenant au moins deux unités mononucléotide comportant chacune des groupes phosphate ou polyphosphate distincts liés aux radicaux saccharide des groupes nucléoside, p.ex. acides nucléiques avec le désoxyribosyle comme radical saccharide
UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. (USA)
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (USA)
Inventeur(s)
Burdick, Joel W.
Tai, Yu-Chong
Naber, John F.
Keynton, Robert S.
Edgerton, Victor Reggie
Roy, Roland R.
Gerasimenko, Yury
Harkema, Susan J.
Hodes, Jonathan
Angeli, Claudia A.
Nandra, Mandheerej S.
Desautels, Thomas Anthony
Upchurch, Steven L.
Jackson, Douglas J.
Abrégé
A neurostimulator device for use with groups (e.g., more than four groups) of electrodes. The neurostimulator may include a stimulation assembly configured to deliver different stimulation to each of the groups. The neurostimulator may also include at least one processor configured to direct the stimulation assembly to deliver stimulation to the groups. The stimulation delivered to at least one of the groups may include one or more waveform shapes other than a square or rectangular wave shape. The processor may receive data from one or more sensors and use that data to modify the stimulation delivered. The neurostimulator may be configured to communicate with an external computing device. The neurostimulator may send data to and/or receive data and/or instructions from the computing device. The computing device may use information collected by one or more sensors to at least partially determine stimulation parameters to communicate to the neurostimulator.
A61N 1/36 - Application de courants électriques par électrodes de contact courants alternatifs ou intermittents pour stimuler, p.ex. stimulateurs cardiaques
A61N 1/05 - Electrodes à implanter ou à introduire dans le corps, p.ex. électrode cardiaque
A61N 1/08 - Aménagements ou circuits de surveillance, de protection, de commande ou d'indication
77.
A PARYLENE-BASED MICROELECTRODE ARRAY IMPLANT FOR SPINAL CORD STIMULATION
UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. (USA)
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (USA)
Inventeur(s)
Nandra, Mandheerej S.
Edgerton, Victor Reggie
Roy, Roland R.
Gerasimenko, Yury
Tai, Yu-Chong
Angeli, Claudia A.
Burdick, Joel W.
Rodger, Damien Craig
Fong, Andy
Lavrov, Igor
Harkema, Susan J.
Abrégé
An implantable electrode array assembly configured to apply electrical stimulation to the spinal cord. A substantially electrically nonconductive layer of the device has a first portion positionable alongside the spinal cord that includes a plurality of first openings. The layer has a second portion that includes a plurality of second openings. Electrodes and traces are positioned inside a peripheral portion of a body portion of the device and alongside the layer. At least one of the first openings is adjacent each of the electrodes to provide a pathway through which the electrode may provide electrical stimulation to the spinal cord. At least one of the second openings is adjacent each of the traces to provide a pathway through which the trace may receive electrical stimulation. At least one trace is connected to each electrode and configured to conduct electrical stimulation received by the trace(s) to the electrode
A61N 1/05 - Electrodes à implanter ou à introduire dans le corps, p.ex. électrode cardiaque
A61B 18/00 - Instruments, dispositifs ou procédés chirurgicaux pour transférer des formes non mécaniques d'énergie vers le corps ou à partir de celui-ci
A61N 1/18 - Application de courants électriques par électrodes de contact
A61N 1/36 - Application de courants électriques par électrodes de contact courants alternatifs ou intermittents pour stimuler, p.ex. stimulateurs cardiaques
78.
HIGH DENSITY EPIDURAL STIMULATION FOR FACILITATION OF LOCOMOTION, POSTURE, VOLUNTARY MOVEMENT, AND RECOVERY OF AUTONOMIC, SEXUAL, VASOMOTOR, AND COGNITIVE FUNCTION AFTER NEUROLOGICAL INJURY
UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. (USA)
Inventeur(s)
Gerasimenko, Yury
Burdick, Joel
Hodes, Jonathan
Tai, Yu-Chong
Angeli, Claudia A.
Edgerton, Victor Reggie
Roy, Roland R.
Harkema, Susan J.
Nandra, Mandheerej S.
Desautels, Thomas Anthony
Abrégé
Methods of enabling locomotor control, postural control, voluntary control of body movements (e.g., in non-weight bearing conditions), and/or autonomic functions in a human subject having spinal cord injury, brain injury, or neurological neuromotor disease. In certain embodiments, the methods involve stimulating the spinal cord of the subject using an epidurally placed electrode array, subjecting the subject to physical training thereby generating proprioceptive and/or supraspinal signals, and optionally administering pharmacological agents to the subject. The combination of stimulation, physical training, and optional pharmacological agents modulate in real time electrophysiological properties of spinal circuits in the subject so they are activated by supraspinal information and/or proprioceptive information derived from the region of the subject where locomotor activity is to be facilitated.
A61N 1/36 - Application de courants électriques par électrodes de contact courants alternatifs ou intermittents pour stimuler, p.ex. stimulateurs cardiaques
A61H 1/00 - Appareils pour l'exercice passif; Appareils vibrateurs; Dispositifs de chiropractie, p.ex. dispositifs pour appliquer des chocs au corps, dispositifs externes pour étirer ou aligner de façon brève des os non fracturés
Provided is a method and a composition for improving behavioral performance in an individual comprising identifying an individual in need of treatment, and providing such an individual a composition comprising bacteria within the genus Bacteroides.
COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (France)
CALIFORNIA INSTITUTE OF TECHNOLOGY (USA)
Inventeur(s)
Puget, Pierre
Myers, Edward B.
Roukes, Michael L.
Abrégé
A system for analyzing a gas mixture, including at least one chromatography column (4), means (2) for injecting said mixture into said column (4), and means (6) for detecting the compound(s) fonning the gas mixture, the detection means (6) including at least one detector of the nanosensor type at the outlet of the column and a detector of the nanosensor type in the column, capable of detecting the passage of the compounds. It is then possible to detennine the velocity of each of the compounds within the system.
The present invention relates to recombinant microorganisms comprising biosynthetic pathways and methods of using said recombinant microorganisms to produce various beneficial metabolites. In various aspects of the invention, the recombinant microorganisms may further comprise one or more modifications resulting in the reduction or elimination of 3 keto-acid (e.g., acetolactate and 2-aceto-2-hydroxybutyrate) and/or aldehyde-derived by-products. In various embodiments described herein, the recombinant microorganisms may be microorganisms of the Saccharomyces clade, Crabtree-negative yeast microorganisms, Crabtree-positive yeast microorganisms, post-WGD (whole genome duplication) yeast microorganisms, pre-WGD (whole genome duplication) yeast microorganisms, and non-fermenting yeast microorganisms.
C12N 9/04 - Oxydoréductases (1.), p.ex. luciférase agissant sur des groupes CHOH comme donneurs, p.ex. oxydase de glucose, déshydrogénase lactique (1.1)
C07H 19/20 - Radicaux purine avec le radical saccharide estérifié par des acides phosphoriques ou polyphosphoriques
C12N 1/00 - Micro-organismes, p.ex. protozoaires; Compositions les contenant; Procédés de culture ou de conservation de micro-organismes, ou de compositions les contenant; Procédés de préparation ou d'isolement d'une composition contenant un micro-organisme; Leurs milieux de culture
C12N 1/19 - Levures; Leurs milieux de culture modifiés par l'introduction de matériel génétique étranger
C12P 1/00 - Préparation de composés ou de compositions, non prévue dans les groupes , utilisant des micro-organismes ou des enzymes; Procédés généraux de préparation de composés ou de compositions utilisant des micro-organismes ou des enzymes
C12P 5/02 - Préparation des hydrocarbures acycliques
C12P 7/02 - Préparation de composés organiques contenant de l'oxygène contenant un groupe hydroxyle
The present invention is generally provides recombinant microorganisms comprising engineered metabolic pathways capable of producing C3-05 alcohols under aerobic and anaerobic conditions. The invention further provides ketol-acid reductoisomerase enzymes which have been mutated or modified to increase their NADH- dependent activity or to switch the cofactor preference from NADPH to NADH and are expressed in the modified microorganisms. In addition, the invention provides isobutyraldehyde dehydrogenase enzymes expressed in modified microorganisms. Also provided are methods of producing beneficial metabolites under aerobic and anaerobic conditions by contacting a suitable substrate with the modified microorganisms of the present invention.
C12N 15/00 - Techniques de mutation ou génie génétique; ADN ou ARN concernant le génie génétique, vecteurs, p.ex. plasmides, ou leur isolement, leur préparation ou leur purification; Utilisation d'hôtes pour ceux-ci
Methods for the preparation of saturated imidazolinium salts and related compounds that comprises reaction of formamidines with compounds such as dihaioethane and an optional base are disclosed. Alternatively, the imidazoünium salts and related compounds can be prepared in a one-step process without purification of the formamidine reactant. These methods make it possible to obtain numerous imidazolinium salts and related compounds under solvent-free reaction conditions and in excellent yields.
C07D 233/06 - Composés hétérocycliques contenant des cycles diazole-1, 3 ou diazole-1, 3 hydrogéné, non condensés avec d'autres cycles comportant une liaison double entre chaînons cycliques ou entre chaînon cyclique et chaînon non cyclique avec uniquement des atomes d'hydrogène ou des radicaux ne contenant que des atomes d'hydrogène et de carbone, liés directement aux atomes de carbone du cycle
84.
ARRAYS COMPRISING A PLURALITY OF WELLS, EACH WELL RELEASABLY ATTACHED TO A PATTERNED PLURALITY OF DIFFERENT ANTIBODIES
The disclosure provides an array for the multiplexed analysis of a plurality of biomolecules, wherein each well provides a distinct signature of at least one cell or its cellular components. Exemplary arrays comprise a solid substrate comprising a surface and a plurality of primary antibodies attached thereto in a pattern. The plurality of primary antibodies bind different cellular components. Between 3 and 50 different primary antibodies are attached to the solid surface in the pattern. When a polydimethylsiloxane mold comprising a plurality of wells is releasably coupled with the solid substrate, the plurality of wells are oriented to intersect with the pattern of attached primary antibodies and each well is exposed to the pattern of attached primary antibodies. The selective binding of each primary antibody and its target biomolecule is labeled by a detectable secondary antibody. The resultant pattern of detectable secondary antibodies comprises the distinct signature of each well.
In one aspect, the invention provides methods and compositions for the expression of small RNA molecules within a cell using a retroviral vector (Fig. IA). Small interfering RNA (siRNA) can be expressed using the methods of the invention within a cell. In a further aspect, the invention provides methods for producing siRNA encoding lentivirus where the siRNA activity may interfere with the lentiviral life cycle. In yet a further aspect, the invention provides methods for expression of a small RNA molecule within a cell, such as an siRNA capable of downregulating CCR5, wherein expression of the small RNA molecule is relatively non-cytotoxic to the cell. The invention also includes small RNA molecules, such as an siRNA capable of downregulating CCR5, that are relatively non-cytotoxic to cells.
C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p.ex. oligonucléotides anti-sens
A61K 31/7105 - Acides ribonucléiques naturels, c. à d. contenant uniquement des riboses liés à l'adénine, la guanine, la cytosine ou l'uracile et ayant des liaisons 3'-5' phosphodiester
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiques; Thérapie génique
C12N 15/11 - Fragments d'ADN ou d'ARN; Leurs formes modifiées
C12N 15/63 - Introduction de matériel génétique étranger utilisant des vecteurs; Vecteurs; Utilisation d'hôtes pour ceux-ci; Régulation de l'expression
C07H 21/02 - Composés contenant au moins deux unités mononucléotide comportant chacune des groupes phosphate ou polyphosphate distincts liés aux radicaux saccharide des groupes nucléoside, p.ex. acides nucléiques avec le ribosyle comme radical saccharide
C07K 14/715 - Récepteurs; Antigènes de surface cellulaire; Déterminants de surface cellulaire pour des interférons
C12N 7/01 - Virus, p.ex. bactériophages, modifiés par l'introduction de matériel génétique étranger
86.
TARGETED GENE DELIVERY FOR DENDRITIC CELL VACCINATION
Methods and compositions are provided for delivery of a polynucleotide encoding a gene of interest, typically an antigen, to a dendritic cell (DC). The virus envelope comprises a DC-SIGN specific targeting molecule. The methods and related compositions can be used to treat patients suffering from a wide range of conditions, including infection, such as HIV/AIDS, and various types of cancers.
C12N 15/85 - Vecteurs ou systèmes d'expression spécialement adaptés aux hôtes eucaryotes pour cellules animales
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiques; Thérapie génique
A61P 31/18 - Antiviraux pour le traitement des virus ARN du HIV
Methods and compositions are provided for delivering a polynucleotide encoding a gene of interest to a target cell using a virus. The virus envelope comprises a cell-specific binding determinant that recognizes and binds to a component on the target cell surface, leading to endocytosis of the virus. A separate fusogenic molecule is also present on the envelope and facilitates delivery of the polynucleotide across the membrane and into the cytosol of the target cell. The methods and related compositions can be used for treating patients having suffering from a wide range of conditions, including infection, such as HIV; cancers, such as non-Hodgkin's lymphoma and breast cancer; and hematological disorders, such as severe combined immunodeficiency.
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiques; Thérapie génique
88.
METHOD AND APPARATUS FOR A BRAGG GRATING TUNABLE FILTER
The present invention relates to tunable filters. More specifically, the present invention pertains to a method and apparatus that allows tuning of a wavelength over a large optical band. The disclosed system and method allows an arbitrary wavelength selection of an incoming beam of light. The disclosed system and method may be used in imaging systems like telescopes or microscopes, or for point sources like laser or optical fibers. Further, in the case of optical fibers, it may be used as an add/drop filter.
A functionalized photocurable perfluoropolyether is used as a material for fabricating a solvent-resitant microfluidic device. Such solvent~ resistant microfluidic devices can be used to control the flow of small amounts of a fluid, such as an organic solvent, and to perform microscale chemical reactions that are not amenable to other polymer-based microfluidic devices.
B01D 15/18 - Adsorption sélective, p.ex. chromatographie caractérisée par des caractéristiques de structure ou de fonctionnement relatives aux différents types d'écoulement
B01L 3/00 - Récipients ou ustensiles pour laboratoires, p.ex. verrerie de laboratoire; Compte-gouttes
C08G 65/00 - Composés macromoléculaires obtenus par des réactions créant une liaison éther dans la chaîne principale de la macromolécule
C08G 85/00 - Procédés généraux pour la préparation des composés prévus dans la présente sous-classe
G01N 31/00 - Recherche ou analyse des matériaux non biologiques par l'emploi des procédés chimiques spécifiés dans les sous-groupes; Appareils spécialement adaptés à de tels procédés
brevets
